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AbstrACt 
Objective Hepatocellular carcinoma (HCC) is the third 
leading cause of cancer death worldwide. We conducted 
network meta-regression within a Bayesian framework to 
compare and rank different treatment strategies for HCC 
through direct and indirect evidence from international 
studies.
Methods and analyses We pooled the OR for 1-year, 
3-year and 5-year overall survival, based on lesions of 
size ˂ 3 cm, 3–5 cm and ≤5 cm, using five therapeutic 
options including resection (RES), radiofrequency ablation 
(RFA), microwave ablation (MWA), transcatheter arterial 
chemoembolisation (TACE) plus RFA (TR) and percutaneous 
ethanol injection (PEI).
results We identified 74 studies, including 26 944 
patients. After adjustment for study design, and in the full 
sample of studies, the treatments were ranked in order of 
greatest to least benefit as follows for 5 year survival: (1) 
RES, (2) TR, (3) RFA, (4) MWA and (5) PEI. The ranks were 
similar for 1- and 3-year survival, with RES and TR being 
the highest ranking treatments. In both smaller (<3 cm) 
and larger tumours (3–5 cm), RES and TR were also the 
two highest ranking treatments. There was little evidence 
of inconsistency between direct and indirect evidence.
Conclusion The comparison of different treatment 
strategies for HCC indicated that RES is associated with 
longer survival. However, many of the between-treatment 
comparisons were not statistically significant and, for 
now, selection of strategies for treatment will depend 
on patient and disease characteristics. Additionally, 
much of the evidence was provided by non-randomised 
studies and knowledge gaps still exist. More head-to-
head comparisons between both RES and TR, or other 
approaches, will be necessary to confirm these findings.
IntrOduCtIOn 
Cancer was the second leading cause of death 
in 2013, behind cardiovascular disease, and 
in 2013 more than 8 million people died from 
cancer globally.1–3 Hepatocellular carcinoma 
(HCC) was the sixth most common cancer 
worldwide and the third leading cause of 
cancer death, with 5-year overall survival rates 
under 12%.4 5 
Hepatic resection (RES) was the tradi-
tional choice for patients with HCC, without 
cirrhosis and with good remaining liver func-
tion.6 Despite nearly 70% 5-year survival, 
recurrence rates after surgery were high.7 
Repeated hepatectomies to lengthen survival 
were not often appropriate owing to multi-
ple-site tumour recurrence or patient back-
ground of liver cirrhosis.8 9 Many locoregional 
therapies have been developed including 
ablative treatments such as percutaneous 
ethanol injection (PEI), radiofrequency abla-
tion (RFA) or microwave ablation (MWA) 
and transarterial therapies such as transcath-
eter arterial chemoembolisation (TACE) or 
transarterial chemotherapy infusion (TACI). 
Locoregional therapies were minimally inva-
sive and therefore are cheaper and faster 
to recover, as compared to resection. Such 
approaches may be appropriate for patients 
with unresectable, small or multiple carci-
nomas or those with severe cirrhosis. However, 
there may be a greater risk of recurrence 
strengths and limitations of this study
 ► This is a network meta-regression within a Bayesian 
framework to compare and rank different treatment 
strategies for HCC through direct and indirect evi-
dence from international studies.
 ► Strong and reliable methodological and statistical 
procedures were applied.
 ► The individual or tumour characteristics within HCC 
articles would be a source of heterogeneity.
 ► A major limitation is in the inclusion of non-ran-
domised studies, in which selection bias is likely 
to confound observations. Selection of treatment is 
likely to be based on individual or tumour character-
istics, and thus these factors will bias and confound 
observations of survival.
 ► Other studies did not report the primary outcome of 
interest (5-year survival) and this was a particular 
limitation among randomised studies.
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because of incomplete destruction of cancer cells at the 
treatment margin, as seen with RFA.10
The selection of treatment strategy was determined by 
liver function, tumour stage and patient performance 
status,7 but much uncertainty still remains surrounding the 
comparative efficacy of different treatment approaches. A 
recent review of international guidelines for HCC found 
similarities but also some discrepancy in treatment allo-
cation recommendations because of regional classifica-
tion differences, secondary to a lack of solid or high-level 
evidence.11 A recent review of therapies also revealed that 
there was no consensus on whether surgery or ablation 
was better for small tumours.7 Some discrepancy in prev-
alence and treatment outcomes may be still in different 
regions because of local biology, available resources or 
expertise and access to care.11 However, if we ever hope 
to achieve standardised and evidence-based therapy for 
HCC, the unanswered question surrounding relative 
treatment efficacy of RES compared with ablative locore-
gional therapies should be resolved.
Traditional meta-analysis is limited by existing head-to-
head treatment comparisons within included studies. It is 
therefore not possible to gauge the relative benefit of the 
two treatments that have never been directly compared 
in studies. Real-life treatment decisions are hindered 
by gaps in existing evidence, but network meta-analysis 
enables integration of direct and indirect comparisons to 
provide estimates for relative comparisons across many 
treatments.12 Recent published network meta-analysis 
focused on advanced HCC by TACE alone or combined 
treatments,13 14 as well as antineoplastic drugs (sorafenib, 
erlotinib, linifanib, sunitinib and brivanib),15 and early- 
or very early-stage HCC via surgery or thermal ablation.16 
However, in this study, we included the latest literature, 
and focused on the comparison of interventional and 
surgical treatments, including RES, RFA, MWA and TACE 
plus RFA (TR), PEI using subgroup analysis of tumour 
size (smaller: <3 cm; larger: 3–5 cm) and study design 
(cohort or randomised clinical trial (RCT)). In order 
to investigate comparative effectiveness among RES and 
common locoregional ablative therapies, we performed a 
strong and reliable Bayesian network meta-analysis.
seArCh strAtegy
We conducted a systematic review and report findings in 
accordance with Preferred Reporting Items for System-
atic Reviews and Meta-Analyses for Network Meta-Anal-
yses (PRISMA-NMA)17 (online supplementary text 
S1). The following databases were searched: PubMed, 
Embase, Web of Science and Scopus, up to May 2018, 
using these keywords: resection, surgery, hepatectomy, 
Figure 1 Flow chart of search.
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radiofrequency ablation, transarterial chemoembolisa-
tion, microwave thermal ablation, ethanol injection, liver, 
cancer and tumour (online supplementary text S2). No 
language restrictions were used. Bibliographies from 
other relevant review articles were cross-examined for 
potential missed studies. Disagreement was resolved by a 
third reviewer. Citations were downloaded into reference 
management software and duplicate citations were elec-
tronically or manually removed.
We systematically included the studies using the 
following criteria: (1) original data from prospective or 
retrospective cohort studies and RCTs in humans; (2) 
reporting at least two treatments, including resection 
or any local ablative therapy (RES, RFA, MWA, PEI or 
TACE+RFA (TR)); (3) mean lesion size ≤5 cm and (4) 
evaluating overall survival rate not less than 1 year after 
first or recurrent treatments. Conference abstracts and 
case reports were excluded, as were older publications 
from studies with multiple publications.
Patients and public involvement
The patients or public were not involved in the study.
dAtA extrACtIOn And study quAlIty
Two investigators independently extracted and cross-
checked the data from the eligible studies: author, year, 
study design, country, disease type, inclusion criteria, 
treatment style, study size, gender, age, tumour size, 
follow-up duration, treatment complications and survival 
outcomes. If in disagreement, a third reviewer was asked 
to adjudicate. The level of evidence was appraised using 
the Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) guidance,18 which was 
classified into four levels: high, moderate, low and very 
low. The quality score was downgraded according to five 
domains, including the risk of bias, inconsistency, indi-
rectness, imprecision and publication bias while scores 
were upgraded according to large effect, appropriate 
Figure 2 Networks of treatment comparisons for 1 year (A), 3 year (B), and 5 year (C) survival rates in RCTs. Circle size is 
proportional to the number of included patients and line width indicates the number of studies comparing the connected 
treatments. The number in red indicates the sample size and the number in black indicates the number of studies. (i) Lesions 
<3 cm. (ii) Lesions 3–5 cm. (iii) Lesions≤5 cm.
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control for plausible confounding and dose–response 
gradient.
dAtA AnAlysIs
Network meta-analysis was used if a ring or open evidence 
loop was available to know the number of arms and the 
sample size of each intervention. When possible, pair-
wise direct head-to-head comparisons were conducted 
to calculate the OR of 1-, 3- and 5-year survival and their 
95% CI. Between-study heterogeneity was evaluated using 
the tau-squared statistic (τ).2 19 A node-splitting analysis 
was applied to check the consistency between direct 
evidence (existing real reported comparisons) and indi-
rect evidence (estimated treatment comparisons) for 
their agreement on a specific node.20 Bayesian network 
meta-analysis with Markov chain Monte Carlo (MCMC), 
through a consistency model, was utilised to estimate the 
pooled ORs and its 95% credible interval (CrI) for direct 
and indirect comparisons.16 The inconsistency model was 
used to check for heterogeneity due to chance imbal-
ance in the distribution of effect modifiers. Consistency 
in every closed loop was checked by the loop-specific 
approach in order to estimate whether treatment survival 
effects were disturbed by variance in the distribution 
of potential confounding factors among the studies. In 
order to compare and rank survival rates of different treat-
ments, we examined all studies first and then separately 
assessed smaller (<3 cm) and larger (3–5 cm) tumours. 
Random-effect meta-regression models were used, with 
and without adjustment for study design (cohort or RCT) 
and subgroup analyses were also conducted for RCTs in 
order to examine treatment effectiveness. We appraised 
the ranking probabilities for all therapies for each inter-
vention and the treatment hierarchy was ordered by the 
surface under the cumulative ranking curve (SUCRA).21 
Sensitivity analysis was conducted to remove each study, in 
turn, and estimate the treatment effect in the remaining 
studies. Funnel plots were utilised to check the possible 
Figure 3 Networks of treatment comparisons for 1 year (A), 3-year (B), and 5-year (C) survival rates in all the studies. Circle 
size is proportional to the number of included patients and line width indicates the number of studies comparing the connected 
treatments. The number in red indicates the sample size and the number in black indicates the number of studies. (i) Lesions 
<3 cm. (ii) Lesions 3–5 cm. (iii) Lesions≤5 cm.
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presence of publication bias or small-study bias.22 In this 
study, we used Bayesian MCMC simulations by WinBUGS 
1.4 and graphically presented the results using Stata V.13.
results
study characteristics
After screening, 74 relevant studies in 73 articles were 
identified, of which 20 were RCTs and 54 were cohort 
studies.23–96 We excluded 136 504 duplicate or non-rele-
vant citations (figure 1). The summary characteristics of 
these studies are shown in online supplementary table 
S1. Overall, 32 345 patients of mean age from 46 to 73.5 
years, with approximately 29 236 tumours, were assigned 
to receive RES, RFA, MWA, TR and PEI, and the mean 
follow-up ranged from 1.5 to 5.7 years. In addition, 
the number of connected studies to the lines (black) 
and sample size of each treatment (red) were shown in 
figures 2 and 3, respectively.
network meta-analysis results
Ten possible treatment comparisons among the five 
interventions were examined in the included studies. 
Comparable survival estimates were made for each treat-
ment (per 1000 patients) and the survival OR among each 
of the treatment comparisons, according to follow-up 
duration, are presented in online supplementary table 
S2, along with estimation of the quality of evidence using 
GRADE criteria.
Across the range of treatment comparisons and 
follow-up durations, evidence was graded between low 
and high quality. Evidence was often graded as low quality 
owing to publication bias and graded as high quality owing 
to a larger number of participants in direct comparisons.
Survival probabilities (estimated using Meanrank) 
and ranks for the five treatments in patients with 
tumours <3 cm, 3–5 cm or ≤5 cm (with and without 
adjustment for study design) are graphically displayed 
in figures 2–5, and numerical details are given in online 
supplementary tables S3–S4. RES was consistently associ-
ated with greater survival (rank 1) compared with MWA, 
RFA, TR and PEI for the 5-year survival estimates. The 
ranks were similar for 1- and 3-year survival with RES or 
TR being ranked as 1 or 2 in most analyses. After adjust-
ment for study design, and in the full sample of available 
Figure 4 Treatment ranks for 1-year, 3-year and 5-year survival rates, according to lesion size in RCTs: (A) Lesions <3 cm. 
(B) Lesions 3–5 cm. (C) Lesions≤5 cm (full sample).
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studies (n=74), the treatments were ranked as follows for 
5-year survival: (1) RES, (2) TR, (3) RFA, (4) MWA and 
(5) PEI (online supplementary table S4).
Efficacy comparisons from network meta-regression 
for all treatments are summarised in tables 1 and 2, 
according to follow-up duration and initial tumour size. 
Compared with RES, the 5-year survival in all studies 
(trials and observational studies) for all tumours ≤5 cm, 
was 0.45 (95%CrI 0.23 to 0.82) for PEI, 0.59 (95%CrI 
0.25 to 1.20) for TR, 0.55 (95%CrI 0.25 to 1.05) for 
MWA and 0.52 (95%CrI 0.29 to 0.88) for RFA (table 2). 
When examining the comparisons across all treatments, 
the only significant difference for tumours<3 cm was 
for 5-year survival, and a significantly worse survival was 
observed for PEI compared with RES 0.43 (95%CrI 0.17 
to 0.89). For tumours between 3 and 5 cm, no significant 
differences were observed at 5-year survival, but signifi-
cantly worse 3-year survival was observed with PEI, MWA 
and RFA compared with RES (table 2). Despite smaller 
number of studies in analyses of only RCTs, the pairwise 
comparisons showed similar results. However, all relative 
rankings should be interpreted with caution because 
most network meta-regression comparisons did not 
suggest a statistically significant difference between treat-
ments. Detailed results of each comparison for survival 
rates were shown in online supplementary tables S5–S10.
Loop-specific methods detected no inconsistency 
between the pairwise and network meta-analysis for 
most closed loops in the network (online supplementary 
figure S1). However, inconsistency was observed between 
direct and indirect comparisons for the following loops: 
lesions<3 cm: RES-RFA-TR, PEI-RES-RFA, MWA-RES-RFA; 
lesions 3–5 cm: MWA-RES-RFA, RES-RFA-TR; and 
lesions≤5 cm: RES-RFA-TR). In addition, tests for inconsis-
tency were carried out (online supplementary tables S11–
S13), which indicated a close relationship of between-trial 
heterogeneity and inconsistency between ‘direct’ and 
‘indirect’ evidence.
sensitivity analysis and publication bias
No significant change was observed when any one study 
was deleted. Funnel plots indicated that the included 
studies in each group were distributed symmetrically 
around the vertical line (x=0), suggesting that no obvious 
evidence of publication bias or small-sample effect existed 
in this network (online supplementary figure S2).
Figure 5 Treatment ranks for 1-year, 3-year and 5-year survival rates, according to lesion size in all studies. (A) Lesions <3 cm. 
(B) Lesions 3–5 cm. (C) Lesions ≤5 cm (full sample).
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Table 1 ORs (95% credible interval) according to network meta-analyses for the survival for all pairwise comparisons in 
randomised controlled trials
<3 cm for 1-year survival
PEI
1.17 (0.11 to 4.66) TR
0.08 (0 to 0.38) 0.15 (0 to 0.80) MWA
0.67 (0.28 to 1.35) 1.25 (0.16 to 4.64) 173.30 (1.90 to 537.40) RFA
0.64 (0.18 to 1.61) 1.08 (0.15 to 3.78) 152.70 (1.44 to 505.80) 0.97 (0.42 to 1.98) RES
<3 cm for 3-year survival
PEI
1.02 (0.14 to 3.56) TR
NA NA MWA
0.79 (0.45 to 1.39) 1.54 (0.25 to 13.43) NA RFA
0.58 (0.29 to 1.16) 1.17 (0.16 to 4.17) NA 0.75 (0.41 to 1.31) RES
<3 cm for 5-year survival
PEI
3.93 (0.03 to 19.61) TR
NA NA MWA
0.94 (0.08 to 3.97) 2.87 (0.04 to 13.43) NA RFA
0.50 (0.04 to 2.04) 0.84 (0.03 to 4.18) NA 0.72 (0.10 to 2.47) RES
3 to 5 cm for 1-year survival
PEI
NA TR
NA NA MWA
NA 3.40 (0.64 to 11.93) NA RFA
NA 1.00 (0 to 5.00) NA 0.25 (0 to 1.47) RES
3 to 5 cm for 3-year survival
PEI
NA TR
NA NA MWA
NA 3.98 (0.71 to 15.22) NA RFA
NA 1.14 (0 to 6.20) NA 0.24 (0 to 1.25) RES
3 to 5 cm for 5-year survival
PEI
NA TR
NA NA MWA
NA 7.64 (0.14 to 42.49) NA RFA
NA 12.87 (0.02 to 44.43) NA 1.05 (0.03 to 5.33) RES
≤5 cm for 1-year survival
PEI
0.29 (0.09 to 0.73) TR
0.27 (0.05 to 0.84) 1.09 (0.16 to 3.50) MWA
0.65 (0.33 to 1.13) 2.69 (1.02 to 6.04) 3.84 (0.81 to 11.60) RFA
0.37 (0.13 to 0.82) 1.50 (0.48 to 3.67) 2.01 (0.47 to 5.70) 0.57 (0.27 to 1.08) RES
≤5 cm for 3-year survival
PEI
0.64 (0.19 to 1.67) TR
1.05 (0.12 to 4.56) 1.86 (0.21 to 7.59) MWA
0.86 (0.39 to 1.79) 1.56 (0.66 to 3.25) 1.77 (0.22 to 6.24) RFA
0.55 (0.19 to 1.44) 0.98 (0.35 to 2.41) 1.00 (0.16 to 3.30) 0.65 (0.31 to 1.29) RES
≤5 cm for 5-year survival
PEI
Continued
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dIsCussIOn
There were many techniques for attaining a large ablated 
zone and complete necrosis of HCC and this compre-
hensive review addressed two of the more common treat-
ments, namely resection and ablation. In this network 
meta-analysis, of the five examined therapies, the pooled 
data showed RES ranked best in full sample analysis with 
or without adjustment for study design. In both smaller 
(<3 cm) and larger tumours (3–5 cm), RES remained 
the highest ranking treatment. However, most of the 
individual treatment comparisons were not statistically 
significant and thus, RES may not be superior to all other 
therapies. Our evidence indicated locoregional therapies 
and particularly RES or TR (TACE+RFA) were associated 
with longer survival.
Our observation of better survival outcomes with TR 
may be through the advantage of dual mechanisms. With 
TR, TACE-induced hypoxic injury on cancer cells through 
occlusion of blood vessels and was followed by local abla-
tion. This combination therapy may result in a larger 
ablated zone,97 reducing the possibility of micrometas-
tasis and recurrence, and thus, resulting in better survival 
outcomes than RFA alone.
While being more invasive, and despite risk of compli-
cations, RES was associated with better survival outcomes 
after 1 year, 3 years and 5 years. This may be due to 
removal of larger sections of liver than can be targeted 
with locoregional therapies, thus removing a larger area 
of potentially cancerous cells. Additionally, rat models 
indicated that the liver has the potential to quickly restore 
its original size after partial hepatectomy. This may be 
mediated via interactions of lipopolysaccharide (LPS), 
tumour necrosis factor (TNF)α, interleukin (IL)−6, 
and transforming growth factor β (TGFβ).98 However, 
evidence from rat models and human studies indicated 
that resection success was associated with resection size 
and regeneration was stunted with larger resections.99–101 
The safe limit for remnant liver volume in normal liver 
was approximately 30% of total liver volume, but this 
was estimated to rise to 40%–50% in those with liver 
disease.99 102 Liver resection was recognised as the most 
efficient treatment for HCC but was only applicable for 
less than 30% of all patients. However, developments in 
preoperative imaging techniques, laparoscopic surgery 
and newly developing combinations with chemotherapy 
may extend its application to more advanced tumours.102 
Furthermore, the consistent associations observed with all 
studies and only in RCTs indicated that patient selection 
bias in the observational studies does not wholly explain 
the better survival outcomes with RES.
Overall, we found PEI was associated with shorter 
survival than the other four therapies, a finding which 
is supported in previous studies.24 33 One study reported 
RFA was superior to PEI in achieving short- and long-term 
survival outcomes, although PEI and RFA showed similar 
5-year survival in lesions<3 cm.55 The possible reason 
why PEI is less effective than RFA may be because lesions 
often have a thick capsule and therefore ethanol may not 
distribute through tissues.
There are several limitations in this study. First, a major 
limitation is in the inclusion of non-randomised studies, 
in which selection bias is likely to confound observations. 
Selection of treatment is likely to be based on individual 
or tumour characteristics, and thus these factors will 
bias and confound observations of survival. Second, this 
study included both RCTs and observational studies, in 
which study designs and type of data collection may not 
be comparable. However, findings were consistent among 
both study designs. Third, all included studies did not 
report our primary outcome of interest (5-year survival) 
and this was a particular limitation among randomised 
studies. Fourth, for many individual comparisons, there 
were either no direct comparisons or comparisons from 
only a small number of studies. The lack of evidence may 
increase the risk of bias, which could enlarge or under-
value effect size, and may explain the small inconsistency 
seen between direct and estimated comparisons. Thus, we 
should be cautious in interpreting treatment rankings for 
the different survival times and for different size lesions. 
While adverse events from treatments may differ (not 
evaluated in detail in this review), by examining overall 
survival outcomes in our review, we have taken account of 
both long-term potential benefits and harms from treat-
ments. The focus of these findings should therefore be 
on the overall observation that RES or TR may be supe-
rior in terms of survival, rather than focusing on specific 
OR values for individual treatment comparisons.
In conclusion, the findings of the current Bayesian 
network meta-analysis indicate that RES or TR may be 
among the most effective therapeutic approaches for 
HCC for 5-year survival in both smaller (<3 cm) and 
larger (3–5 cm) lesions. However, evidence was of variable 
quality, and the majority of evidence came from non-ran-
domised studies, which are prone to selection bias and 
knowledge gaps still exist. For not, at the individual 
level, selection of strategies should depend on patient 
0.53 (0.06 to 1.90) TR
NA NA MWA
0.74 (0.16 to 2.00) 2.29 (0.41 to 7.61) NA RFA
0.41 (0.11 to 1.02) 1.35 (0.23 to 4.69) NA 0.66 (0.20 to 1.62) RES
The reference treatment (1.00) for all comparisons is listed to the right hand side.
MWA, microwave ablation; PEI, percutaneous ethanol injection; RES, resection; RFA, radiofrequency ablation; TR, transcatheter arterial chemoembolisation and 
radiofrequency ablation.
Table 1 Continued 
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Table 2 ORs (95% credible interval) according to network meta-analyses for the survival for all pairwise comparisons in all 
studies
<3 cm for 1-year survival
PEI
0.69 (0.14 to 2.13) TR
0.49 (0.18 to 1.10) 1.08 (0.21 to 7.87) MWA
0.68 (0.38 to 1.09) 1.48 (0.34 to 4.23) 1.59 (0.69 to 3.17) RFA
0.63 (0.22 to 1.44) 1.30 (0.28 to 3.88) 1.49 (0.44 to 3.85) 0.94 (0.39 to 1.91) RES
<3 cm for 3-year survival
PEI
0.90 (0.29 to 2.17) TR
1.01 (0.47 to 1.95) 1.38 (0.42 to 3.40) MWA
0.96 (0.59 to 1.50) 1.31 (0.47 to 2.92) 1.02 (0.57 to 1.70) RFA
0.68 (0.30 to 1.39) 0.90 (0.31 to 2.10) 0.73 (0.30 to 1.55) 0.72 (0.37 to 1.30) RES
<3 cm for 5-year survival
PEI
1.07 (0.31 to 2.72) TR
0.86 (0.39 to 1.65) 1.03 (0.28 to 2.73) MWA
0.82 (0.48 to 1.29) 0.99 (0.32 to 2.39) 1.04 (0.50 to 1.77) RFA
0.43 (0.17 to 0.89) 0.49 (0.16 to 0.18) 0.55 (0.19 to 1.25) 0.54 (0.24 to 1.05) RES
3 to 5 cm for 1-year survival
PEI
0.20 (0.05 to 0.54) TR
0.55 (0.09 to 1.76) 3.39 (0.58 to 10.44) MWA
0.49 (0.18 to 1.12) 2.99 (1.14 to 6.58) 1.29 (0.32 to 3.60) RFA
0.06 (0 to 0.31) 0.36 (0.01 to 2.08) 0.15 (0 to 1.00) 0.12 (0 to 0.63) RES
3 to 5 cm for 3-year survival
PEI
0.28 (0.04 to 0.96) TR
0.61 (0.08 to 2.26) 2.62 (0.61 to 7.90) MWA
0.55 (0.12 to 1.69) 2.38 (0.93 to 5.38) 1.15 (0.39 to 2.65) RFA
0.06 (0 to 0.28) 0.26 (0.01 to 1.10) 0.12 (0.01 to 0.53) 0.11 (0.01 to 0.40) RES
3 to 5 cm for 5-year survival
PEI
5.77 (0.01 to 2.84) TR
4.15 (0.04 to 5.18) 11.97 (0.19 to 46.76) MWA
0.86 (0.06 to 2.68) 6.16 (0.27 to 25.58) 1.26 (0.19 to 4.04) RFA
3.02 (0.01 to 2.40) 14.31 (0.04 to 21.06) 1.24 (0.02 to 4.46) 0.69 (0.04 to 3.16) RES
≤5 cm for 1-year survival
PEI
0.34 (0.11 to 0.63) TR
0.81 (0.38 to 1.51) 2.69 (0.99 to 6.00) MWA
0.77 (0.51 to 1.10) 2.55 (1.20 to 4.85) 1.04 (0.55 to 1.76) RFA
0.52 (0.24 to 0.96) 1.72 (0.66 to 3.70) 0.70 (0.29 to 1.39) 0.68 (0.35 to 1.17) RES
≤5 cm for 3-year survival
PEI
0.64 (0.32 to 1.16) TR
0.98 (0.55 to 1.65) 1.65 (0.80 to 3.03) MWA
0.94 (0.64 to 1.34) 1.57 (0.89 to 2.57) 0.99 (0.64 to 1.47) RFA
0.59 (0.30 to 1.04) 0.97 (0.48 to 1.79) 0.62 (0.32 to 1.09) 0.63 (0.37 to 1.01) RES
≤5 cm for 5-year survival
PEI
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and clinical characteristics. To facilitate generation of 
evidence-based recommendations for HCC therapy, and 
to standardise treatment approaches, further head-to-
head comparisons, especially of resection and ablative 
therapies, are required from high-quality RCTs, with long 
follow-up for survival outcomes.
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